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Theoretical studies of energetics and binding
isotope eﬀects of binding a triazole-based
inhibitor to HIV-1 reverse transcriptase†
A. Krzemin´ska,a K. P. S´widerekab and P. Paneth*a
Understanding of protein-ligand interactions is crucial for rational drug design. Binding isotope eﬀects,
BIEs, can provide intimate details of specific interactions between individual atoms of an inhibitor and
the binding pocket. We have applied multi-scale QM/MM simulations to evaluate binding energetics of a
novel triazole-based non-nucleoside inhibitor of HIV-1 reverse transcriptase and to calculate associated
BIEs. The binding sites can be distinguished based on the 18O-BIE.
Introduction
Human immunodeficiency virus (HIV-1) is a cytopathic human
retrovirus that primarily infects CD+ helper T lymphocytes
leading to the loss of their number and function. The progressive
failure of the immune system associated with the loss of pre-
dominant T lymphocytes and other cells critical to this system,
e.g. macrophages or dendritic cells, leads to acquired immune
deficiency syndrome (AIDS). The progressive disappearance of
immunity weakens the body, allows opportunistic infections
to evolve, leads to cancers and ultimately to premature death.1
Nowadays, treatment of HIV-1 infected patients relies on cocktails of
diﬀerent drugs. Due to undesired side-eﬀects, especially occurring
during long-term treatments, there has been considerable interest
in developing new inhibitors targeting three HIV-1 enzymes: inte-
grase (IN), protease (PR) and reverse transcriptase (RT).2 Herein we
focus on an inhibitor of the latter enzyme.
HIV-1 RT is an asymmetric heterodimer, composed of p66
and p51 subunits, which catalyses the transcription of single-
stranded viral RNA into viral DNA double helices.3 The enzyme
contains one DNA polymerase active site and one ribonuclease
H (RNase H) active site, both of which reside in the p66 subunit
in spatially distinct regions while the smaller p51 chain is
responsible for structural scaﬀolding. The hydrophilic polymerase
active site is located between palm (light blue), finger (blue) and
thumb (cyan) subdomains (see Fig. 1) and is made up of
Asp110, Asp185 and Asp186 amino acids that can coordinate
two Mg2+ or two Mn2+ cations.4 The allosteric cavity, composed
of Lys103, Tyr181, Tyr188, Phe227, Trp229, Leu234 and Tyr318
residues5 (highlighted in Fig. 1), lies approximately 10 Å from
the polymerase active site. The RNase H active site comprising
Asp443, Asp498 and Asp549 amino acids and two bound Mg2+
cations6 is located 60 Å from the allosteric pocket. The two
active sites and the allosteric cavity constitute a key target of
antiviral research. Nucleoside reverse transcriptase inhibitors
(NRTIs) inhibit the polymerase active site and need to be
phosphorylated by cellular kinases to active triphosphate form,
which competes with natural dNTPs and finally becomes incor-
porated into the growing primer. Nucleotide reverse transcriptase
inhibitors (NtRTIs), in contrast to NRTIs, are structures already
Fig. 1 Representation of HIV-1 RT with two binding sites, allosteric cavity
(upper right box) and RNase H active site (lower right box) with a bound
L-1 inhibitor.
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equipped with the phosphonate group and after the phosphoryl-
ation step are able to terminate DNA synthesis also by the com-
petitive mechanism.7 Non-nucleoside RT inhibitors (NNRTIs), on
the other hand, follow the non-competitive mechanism of inhibi-
tion. They are considered to be highly specific compounds that
bind tightly in the allosteric pocket, acting on the enzyme subunits
as a molecular wedge.8,9 Simultaneous inhibition by combining
nucleoside and non-nucleoside inhibitors is also currently
explored.10,11 To date eight NRTIs, two NtRTIs and five NNRTIs
have been approved by FDA.12 In the present study we focus on
a ligand that can bind either in the allosteric cavity or the
RNase H active site of HIV-1 RT and compare it to ligands
designed specifically for one of these sites (structural formulas
of all ligands are presented in ESI,† Fig. S1).
An accurate description of binding aﬃnity of an inhibitor to an
enzyme is still a challenging task.13,14 Nevertheless, using Monte
Carlo simulation, Jorgensen and co-workers estimated binding
aﬃnities of several NNRTIs.15–18 Binding energies of NNRTIs have
also been studied by MM-PBSA19 and quantum calculations20
including the ONIOMmethod.21 Warshel and co-workers obtained
the absolute binding free energies of NNRTIs by the PDLD/S-LRA/b
method.22 Our own experience, first validated on the FDA
approved drugs, indicates that binding free energies of HIV-1
RT complexes with NNRTIs and NRTIs can be efficiently obtained
using a thermodynamic cycle from alchemical free energy per-
turbation (FEP) calculations.23,24
Recently, Schrammand co-workers showed that binding isotope
eﬀects, BIEs,25 exhibit diﬀerent values upon binding an inhibitor,
para-aminobenzoic acid, to an enzyme (dihydropteroate synthase)
from diﬀerent sources (Staphylococcus aureus and Plasmodium
falciparum). In this communication we extend these findings to the
identification of the binding site within a single enzyme using BIEs
on the example of a novel potent HIV-1 RT triazole-based inhibitor.
Computational modelling andmethods
System setup
Novel triazole derivative N-(2-chloro-4-sulphamoylphenyl)-2-
((4-(2,4-dimethyl-phenyl)-5-(thiophen-2-yl)-4H-1,2,4-triazol-3yl)-
sulphanyl)-acetamide, L-1,26 which was found to be a potent
NNRTI, has been docked to the allosteric cavity and the RNase
H active site of HIV-1 RT based on the crystallographic structure
from the Protein Data Bank with PDB ID 2RKI27 using Glide
package as implemented in the Schro¨dinger program.28 Both
complexes are depicted in Fig. 1. The 2RKI structure was
crystalized with 4-benzyl-3-[(2-chlorobenzyl)sulfanyl]-5-thiophen-
2-yl-4H-1,2,4-triazole mole-molecule bound in the allosteric
cavity. The native ligand was removed from 2RKI and L-1 was
docked to the allosteric cavity and to the active site using Glide
XP.29 The pKa for titratable amino acids was calculated using
PROPKA3.0.30–32 Assuming a physiological pH value, hydrogen
atoms were added using the tLEAP module of AMBER program.33
Neutralization of the L-1-allosteric cavity and L-1-RNase H active
site complexes was completed by adding 15 and 9 Cl counterions,
respectively. Finally, both complexes were placed in orthorhombic
boxes of TIP3P34 water molecules of 144  160  144 Å3.
Parameters for L-1 were obtained from GAFF35 as implemented
in AMBER Tools. Afterwards, several optimization and dynamics
simulations were performed using AMBER ff0336 implemented in
NAMD37 program with a time step of 1 fs and periodic boundary
conditions using the particle mesh Ewald method.38 The cut-off
for nonbonding interactions was applied using a smooth
switching function with a radius range from 14.5 to 16 Å. First
energy optimizations were carried out by means of the conjugated
gradient algorithm. The systems were heated by increasing tem-
perature from 0 to 300 K with 0.001 K increment. The equilibration
of the systems was achieved during 300 ps of Langevin–Verlet
dynamics at 300 K. Then 2 ns of NVT MM MD were carried out.
Subsequently, 200 ps for the L-1-cavity and 1 ns for L-1-RNase H
complexes were simulated using QM/MM MD simulations at the
AM139/AMBER:TIP3P theory level as implemented in fDynamo.40 All
atoms beyond 20 Å from L-1 were kept frozen. In order to describe
the binding energy of L-1 to HIV-1 RT, a reference system of L-1 in
an aqueous solution of the equivalent size (144 160 144 Å3) was
simulated during 200 ps of AM1/TIP3P dynamics.
Alchemical free energy perturbation (FEP) method
The enzyme–ligand binding affinity is a main goal of drug design.
Among the different methods developed for this purpose,
the alchemical free energy perturbation (FEP) combined with
QM/MM molecular dynamics, while not providing detailed
information about the full binding process, delivers reliable
values of binding free energy, DDGbind, at a reasonable compu-
tational cost. The FEP method by means of the thermodynamic
cycle was first introduced by Warshel and co-workers.41 Herein,
a series of QM/MM MD have been carried out at 300 K in the
NVT ensemble with two parameters l and g, which correspond
to electrostatic and van der Waals interactions, respectively:
EQM=MMðl; gÞ ¼ C cH0 CD E
þ l
X
C
qMM
re;MM
 C þXXZQMqMMrQM;MM
 
þ gEvdwQM=MM þ EMM
(1)
Both l and g were smoothly changed from 0 to 1 with 0.02
increments. According to our own experience with HIV-1 RT
FEP calculations in each window 5 ps of relaxation followed by
100 ps of QM/MM MD need to be carried out and a simplified
thermodynamic cycle, depicted in Fig. 2, can be used to obtain
DDGbind based on eqn (2).
DDGbind ¼ DGW  DGE ¼ D GelectQM=MM  GvdwQM=MM
 
w
 D GelectQM=MM  GvdwQM=MM
 
E
(2)
The potential energy
In order to describe individual interactions between allosteric
cavity amino acids and the triazole molecule, the analysis of
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averaged potential energy has been performed through QM/
MM MD based on eqn (3)
EINTQM=MM ¼ EelecQM=MM þ EvdwQM=MM ¼
X
MM
C
qMM
re;MM
 C 	
þ
X
QM
ZQMqMM
rQM;MM


þ
XX
4eQM;MM
sQM;MM
rQM;MM
 12"
 sQM;MM
rQM;MM
 6#
(3)
where EINTQM=MM is composed of electrostatic, E
elect
QM=MM, and
van der Waals, EvdwQM=MM, interaction terms as a function of
interaction energy between QM and MM parts. The polarized
QM subsystem includes the coulombic interaction of the QM
nuclei (ZQM) and the electrostatic interaction of the polarized
electronic wave-function (C) with enzyme amino acid charges
(qMM), while the MM part brings non-polarizable potential
contribution.
Molecular electrostatic potential (MEP)
The molecular electrostatic potential, MEP, describes the inter-
action energy between the charge distribution of a molecule
and a unit positive charge. This method allows predicting
nuclear and electronic charge distribution of a given molecule.
Despite the fact that polarization is not included, charge dis-
tribution remains unperturbed by the external test charge, and
the MEP is still eﬀective for the interpretation and prediction of
chemical reactivity.42 Three-dimensional MEP surfaces for L-1
extracted from the allosteric cavity and the RNase H active site
were obtained at the B3LYP/6-31+G(d,p) theory level using
Gaussian09.43 Negative electronic potential corresponds to
the most nucleophilic regions (red), while positive electronic
potential indicates the most electrophilic regions (blue).
Binding isotope eﬀects (BIEs)
Binding isotope eﬀects can provide information on conforma-
tional changes and ligand–enzyme interactions.44 In combination
with the experimental values they can also be used to determine
the actual binding site. We have already successfully used BIEs to
analyse interactions between ligands and HIV-1 RT.24 BIEs can be
expressed by the binding free energy of the light, L, and heavy, H,
isotopologs considering the relationship between the binding free
energy and the equilibrium constant:
BIE ¼
Qe
Qw
 
L
Qe
Qw
 
H
e DZPELDZPEHð Þ=RT (4)
where the total partition function Qe, for the ligand in the
enzyme–ligand complex, and Qw, for the ligand in the ligand–
water complex, are computed as products of the translational,
rotational and vibrational partition functions. The different con-
tributions were separately computed using the Born–Oppenheimer,
rigid rotor and harmonic oscillator approximations. Due to the fact
that in each case the ligand is in a condensed phase, rotational and
translational motions are replaced by six librational motions of the
ligand within its external environment. However, we decided to
subject the full 3N  3N Hessians for the ligand to a projection
procedure to eliminate translational and rotational components,
which gives rise to small non-zero frequencies, as previously
described.44,45 Thus, it has been assumed that the 3N  6 vibra-
tional degrees of freedom are separable from the 6 translational
and rotational degrees of freedom of the substrate (in contrast to
ref. 46). Although the environment (protein or water) surrounding
the ligand affects the values of each Hessian, there is no coupling
between the ligand and its environment. Eleven snapshots from
last 20 ps of QM/MMMD calculations were extracted for L-1-water,
the L-1-allosteric cavity and L-1-RNase H active site complexes. The
combination of 121 BIE individual values obtained with eleven
enzyme–ligand and eleven ligand–water (11  11) structures
allowed for the calculations of BIEs with their uncertainties. All
formalisms used for BIE calculations yielded practically the same
values (see Tables S1 and S2 in the ESI†).
Results and discussion
The obtained total free energies of binding inhibitors to HIV-1
RT binding sites are collected in Table 1. A more extensive
comparison is presented in Fig. 3. There are some diﬃculties in the
validation of DDGbind using experimental data. Our experience
shows that IC50 measurements are not suitable for this purpose
23,24
in contrast to the reciprocal of the dissociation constant (KI) of
the protein–ligand complex.47 Unfortunately, no systematic study of
KI values of different NNRTIs measured under the same experi-
mental conditions can be found in the literature. The evaluation of
our FEP calculations was made by using NRTI23 and NNRTI24 drugs
approved by FDA, where structures of NRTIs correspond to
2,7-dihydroxy-4-1(methylethyl)-2,4,6-cycloheptatrien-1-one (LNA-1),
3-cyclopentyl-1,4-dihydroxy-1,8-naphthyridin-2(1H)-one (LNA-2),
Fig. 2 Thermodynamic cycle to compute enzyme–ligand binding free
energies from the FEP method, where (E) is the enzyme with ligand (L) in
its binding site, E0 is the apo form of enzyme, and (L)0 is the ligand in the
gas phase.
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ethyl 1,4-di-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxyl-
ate (LNA-3), and 3-[4-(diethylamino)phenoxy]-6-(ethoxycarbonyl)-5,8-
dihydroxy-7-oxo-7,8-dihydro-1,8-naphthyridin-1-ium (LNA-4), while
structures of NNRTIs correspond to nevirapine (LNN-1), efavirenz
(LNN-2), rilpivirine (LNN-3), etravirine (LNN-4), and delavirdine
(LNN-5), for more details see Fig. S1 in the ESI.† In a hydro-
phobic pocket van der Waals interactions are the most favour-
able, as observed for NNRTIs. van der Waals interactions are
responsible for the strong (29.2 kcal mol1) binding of L-1 in
the allosteric cavity. It is worth noticing that electrostatic
interactions between L-1 and both water molecules and the
allosteric site have the same DGelect value which indicates that the
electrostatic term does not influence protein–ligand interactions.
In this case the magnitude of the total energy of binding of L-1 to
the allosteric cavity is thus solely due to the van der Waals term
(see the green bars in Fig. 3), which is preferable in the hydro-
phobic pocket. Usually, the van der Waals term is much smaller
than the electrostatic term, hence the relative DDGvdW value
obtained for L-1 is the highest among NNRTIs. This makes L-1
one of the most potent NNRTIs. Binding of L-1 to the RNase H
active site is due to preferable electrostatic forces with DDGbind
equal to 36.5 kcal mol1.
There is a meaningful diﬀerence between L-1 interactions in
aqueous solution and the enzyme environment in both electro-
static and van der Waals terms. NRTIs show the same beha-
viour in the case of electrostatic interactions, but opposite in
van der Waals interactions. Consequently, binding L-1 to the
RNase H site is accompanied by both strong electrostatic and
van der Waals terms, and indicates that L-1 can successfully
bind into the RNase H active site. The potential energy of
electrostatic and van der Waals interactions between L-1 and
allosteric cavity amino acids has been obtained along the
QM/MM dynamics; the averaged results are displayed in Fig. 4.
Negative values correspond to favourable interactions and stabi-
lize the enzyme–ligand complex, while positive values represent
unfavourable interactions. The strength of interactions depends
Table 1 The total free energy of binding (kcal mol1), DDGbind, inhibitors to HIV-1 RT binding sites obtained from the FEP method. DGelect and DGvdW
components correspond to the electrostatic and van der Waals terms, respectively, aq indicates the ligand in aqueous solution while HIV in an enzymatic
environment
Inhibitor Cavity DGelect-aq DGelect-HIV DDGelect DGvdW-aq DGvdW-HIV DDGvdW DDGbind
L-1 RNase H 33.6 56.2 22.5 37.2 51.2 14.0 36.5
L-1 Allosteric 33.6 33.6 0.0 37.2 66.4 29.2 29.2
LNA-3 RNase H 8.2 37.7 29.5 23.1 23.8 0.7 30.2
LNN-3 Allosteric 7.1 14.9 7.8 29.5 50.9 21.4 29.2
Fig. 3 Contributions of electrostatic and van der Waals terms to total binding free energy obtained from FEP calculations.
Fig. 4 Analysis of potential energy of interactions between L-1 and allosteric
cavity amino acids.
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on the nature of the ligand (size, stereochemistry, number and
type of functional groups) and differs among NNRTIs. The
crystallographic structures5,48 indicate that Leu100, Lys101,
Lys103, Val106, Thr107, Val108, Val179, Tyr181, Tyr188, Val189,
Gly190, Phe227, Trp229, Leu234, and Tyr318 all from chain A
and Glu138 from chain B are usually responsible for inhibitor–
enzyme interactions. The L-1-allosteric cavity complex has mean-
ingful interactions with Leu100, Lys103, Lys104, Val106 and
Pro236 as shown in Fig. 4. L-1 interacts also with Phe227,
His235 and Tyr318. Residues Lys101, Thr107, Val108, Val189,
Gly190, Trp229, Leu234, and Tyr318 are too far, while Val179,
Tyr181, Tyr188, and Glu138 from chain B exercise negligible
bending affinity toward L-1. The main contribution of favourable
electrostatic interactions, shown in Fig. 4 and 5, is observed
between 1,2-triazole nitrogen atoms and Lys103. However, these
interactions do not enhance binding affinities, because inter-
actions of L-1 with hydrogen atoms of solvent molecules fully
compensate them. Significantly weaker are favourable electro-
static interactions with Lys104 and Tyr318, wherein carbonyl
oxygen from Lys104 interaction with the hydrogen atom from the
aromatic ring is further stabilized by the p-stacking with Tyr318.
These positive electrostatic interactions are compensated by the
electrostatic repulsion of Asp192. The determinant factor of
L-1-RT attraction comes from the van der Waals interactions,
not present in water, especially with Val106, Leu100, Pro236, and
His235. Residues Tyr181 and Tyr188 are stabilizing one aromatic
ring of L-1 with two methyl groups and Phe227 interacts by
p-stacking with another aromatic ring neighbouring the sulphate
group. The electrostatic positive and negative terms are equal,
therefore the binding process is a result of van der Waals
interactions between L-1 and the allosteric cavity; the potential
energy of van der Waals interactions is sufficient for incorporat-
ing and maintaining L-1 in this hydrophobic pocket.
In contrast to the L-1-allosteric cavity complex, the electro-
static interactions between L-1 and RNase H active sites are
crucial to hold the ligand in the active site centre. The RNase H
active site is made up of Asp443, Glu478, Asp498 and Asp549
amino acids, which coordinate two Mg2+. The magnesium cation
tends to create six coordination bonds but in the active site
usually only five are occupied. Hence, two cations can interact
with ligands by two relatively strong coordination bonds (Fig. 6).
Small ligands, like LNA-1,
23 interact with both Mg2+ without
reorganizing active sites. An opposite situation is observed for
bigger molecules such as LNA-4 and L-1. Both alter the RNase H
active site in the same way, causing an increase of the distance
between magnesium cations and forcing coordination of Val552
and Ser553 by one Mg2+. The open and flexible character of the
RNase H region supports the reorganization of the active site.
This dynamic eﬀect, observed along MM MD, supports binding
of a bigger ligand such as L-1.
Recently, eﬀective medical treatment of HIV infection has
been focused on the composite approach combining diﬀerent
targets (enzymes) of the virus as well as diﬀerent sites within a
single enzyme. It is assumed that inhibitors of diﬀerent types
bind to diﬀerent sites of the enzyme. However, recent reports on
finding several alternative binding sites within HIV-1 RT shed
new light on the actual binding sites of particular inhibitors.49 In
order to analyse the specificity of the triazole-based inhibitors we
have performed calculations of the binding energetics of L-1 in
two binding spots: the allosteric centre and the RNase H active
site. After QM/MM MD simulations we have extracted the last
structure of L-1 from the L-1-cavity and L-1-RNaseH complexes,
and calculated three-dimensional MEP surfaces. The obtained
MEP surfaces are shown in Fig. 7, where the most nucleophilic
regions are in red (0.1 a.u.) and the most electrophilic regions
are in blue (+0.1 a.u.). Both structures have similar distribution
of nuclear and electronic charges. As expected, the triazole ring
and the sulphate group exhibit negative electronic potential.
The sulphate group is dangling almost outside of the hydro-
phobic pocket, thus it can interact with water molecules. In the
L-1-RNase H complex, the active site is open to the aqueous
environment and also in this case the sulphate group can
interact with solvent molecules. The L-1 nitrogen atoms are
deep inside the allosteric cavity and in the presence of Lys103
they act as nucleophiles, while in the RNase H active site
they interact electrostatically with Asp498, Gln500 and Tyr501.
Consequently, there is no big diﬀerence between the charge
distribution of L-1 extracted from an allosteric cavity and from
the RNase H active site. These results indicate that L-1 can bind
to both binding sites.
Fig. 5 Arrangement of L-1 at the allosteric cavity with the average of key
distances in Å.
Fig. 6 Arrangement of L-1 at the RNase H active site with average key
distances in Å. Magnesium cations are highlighted as green balls.
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Another analysis of interactions of L-1 in complexes with the
allosteric cavity and the RNase H active site has been based on
heavy atom (13C, 15N, 18O, 37Cl and 34S) BIEs. The calculated
values are collected in Fig. 7. BIEs can provide information on
diﬀerences in interactions between L-1 dissolved in water and
bound in RT binding sites. Despite the dissimilarity in the
molecular character of the hydrophobic cavity and the hydro-
philic RNase H active site, in both RT binding sites lack of BIEs
for most of the atoms has been observed. The largest isotope
eﬀects were obtained for 18O of the sulphate group and appar-
ently this isotope eﬀect can be experimentally used to distinguish
the place in which L-1 is bound; a normal 18O-BIE (1.016 0.002)
is expected when L-1 binds in the allosteric cavity, where oxygen
atom interacts (see Fig. 4) with the hydrogen atom from Val106
(the distance is 4.23 Å) and is also surrounded by three water
molecules. On the other hand an inverse BIE (0.988  0.002) for
sulphate group 18O atoms is expected for the complex of L-1 with
RNase H, originating from strong interactions with one of the
active site Mg2+ cations (the distance is 2.41 Å) and additionally
from stabilization by the hydrogen atom (the distance is also
2.41 Å) from the methyl group of Ala445 and one water molecule.
Isotope eﬀect diﬀerentiation of the other oxygen of the sulphonyl
group is not possible as it is only slightly inverse (0.997  0.001)
when L-1 is bound in the RNase H active site in contrast to the
lack of the isotope eﬀect of this oxygen atom in the allosteric
cavity. This slightly inverse value of BIE originates from the
interaction with the second Mg2+ cation (the distance is 2.56 Å).
Although electrostatic interaction between the nitrogen atom
of the triazole ring and the hydrogen atom from Lys103 (the
distance is 2.52 Å) is unfavourable in the allosteric cavity, while
in the RNase H active site electrostatic interactions of this atom
with Gln500 and Tyr501 hydrogen atoms tend to stabilize the
complex (the distances are 2.55 Å and 2.10 Å, respectively), there
is no reflection of these diﬀerences in the isotopic binding
patterns with both 15N-BIEs being slightly inverse (0.997 0.001)
and equal. Finally, a negligible normal BIE (1.002  0.002) was
calculated for the 37Cl-BIE when L-1 binds in the RNase H active
site, and a similar value was obtained when L-1 is complexed in
the allosteric cavity. Although it should be kept in mind that
equilibrium isotope eﬀects, such as BIEs, are generally small and
hard to measure experimentally, the above analysis illustrates
that it is possible to distinguish binding sites based on their
values in favourable cases.
Conclusions
The novel inhibitor of HIV-1 RT, L-1, has been proposed and
has been examined based on theoretical simulations. The L-1
molecule was docked to both RT binding sites: allosteric cavity
and RNase H active site. Final complexes of the L-1-binding site
have been obtained after long QM/MM dynamics. Once the
stability of both systems was confirmed, the interactions between
L-1 and RT binding sites have been quantified by free energy of
binding computed using the FEP method. The analysis of this
aﬃnity has been also enriched by potential energy calculations,
three-dimensional MEP isosurfaces, structural analysis and heavy
atom (13C, 15N, 18O, 37Cl and 34S) BIEs. The obtained results
confirmed the diﬀerences between the allosteric cavity and the
RNase H binding sites, as well as dissimilarity in the ligand
binding pathways. In the allosteric cavity the inhibitor binds by
van der Waals aﬃnities, which are preferable in this hydrophobic
pocket, while the electrostatic interactions are unfavourable. The
opposite situation was observed for binding the ligand to the
RNase H active site, where binding occurs by electrostatic forces.
Inhibition is accompanied by the release of standard free
energy, DDGbind. The values of DDGbind were obtained by the
alchemical FEP method. Comparison of diﬀerent NNRTIs, and
NRTIs, L-1 bound in the allosteric cavity and the RNase H active
site shows that L-1 has the largest negative standard free energy of
binding, indicating that L-1 is able to successfully inhibit both the
allosteric cavity and RNase H sites. Also the three-dimensional
MEP isosurface display shows that there is no large diﬀerence
between L-1 charge distribution in the allosteric cavity and the
RNase H active site.
BIE values are almost identical for both L-1-enzyme com-
plexes, with one exception. In contrast to the L-1-allosteric cavity
complex, where a normal (larger than unity) 18O-BIE is expected,
in the L-1-RNase H active site an inverse BIE for two oxygens from
the sulphate group is predicted. This occurs due to the strong
interactions with two Mg2+ originally belonging to the RNase H
active site. Thus BIEs allow us to distinguish to which site L-1
binds. Experimental determination of this 18O-BIE is being
currently carried out in our laboratory.
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